Currently, there are a number of clinical and molecular markers known to be predictive of prognosis in CLL that can be applied to discriminate patients that are more likely to develop a ...

At least one of the following must be present to determine active CLL. Additionally, certain genetic markers, such as deletion 17p or mutation in the TP53 gene, suggest a more aggressive disease ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

This study is the first to look at genetic markers in patients with multiple ... Currently, it has been approved to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

During the last few decades, several markers have been discovered that are predictive of clinical outcome in CLL. These include traditional clinical and serum-based markers, but also the more ...